Document is current
Any future updates will be listed below
-
Authors
Sarkies, Mitchell
Calder, Madeline
Sullivan, David
Srinivasan, Shubha
Spinks, Catherine
Belramoul, Emile
Trent, Ronald J.
Trumble, Claire
Hespe, Charlotte
Li, Stephen C. H.
Elias, Luke
Goodger, Brendan
Birkenhead, Karen
- License Information
-
More Information
Article History
Received: 11 January 2026
Accepted: 26 May 2026
First Online: 6 June 2026
Declarations
Ethics approval and consent to participate: This study was approved by the Ethics Review Committee (RPAH Zone) of the Sydney Local Health District (Protocol ID X22-0333). Participants gave informed consent to participate in the study before taking part.
Consent for publication: Not applicable.
Competing interests: David Sullivan – Grants or contracts from Regeneron, Amgen, Arrowhead, Ionis, Novartis, and MSD; Consulting fees: Amgen and Novartis; Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events: Amgen and Novartis; Participation on a Data Safety Monitoring Board or Advisory Board: LIPID Study, FIELD Study, and Nomad Study, NHMRC Clinical Trials Centre; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: Clinical Committee Chairman, Australian Atherosclerosis Society Executive; Receipt of equipment, materials, drugs, medical writing, gifts or other services: Sanofi Alirocumab samples. Shubha Srinivasan – Payment or honoraria for lectures, presentations: Amgen. Luke Elias – Board of Director member for Heart Support Australia. Karen Birkenhead – member of the Editorial Board of Implementation Science Communications.
